References
- Thow JC, Johnson AB, Fulcher G, et aL. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 1990; 7: 600–602.
- Thow JC, Coulthard A, Home PD. Insulin injection site tissue depths and localisation of a simulated insulin bolus using a novel air con-trast ultrasonographic technique in insulin treated diabetic subjects. Diabet Med 1992; 9: 915–920.
- Bantle JR Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type 1 diabetes subjects. Diabetes Care 1993; 16: 1592–1597.
- Engstrom L, Bergman A. A new injection technique for insulin treat-ment, simpler to use and as effective? Scand J Caring Sci 1993; 7: 57–59.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
- Stratton IM, Adler Al, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321: 405–412.
- American Diabetes Association. Insulin administration. Diabetes Care 2004; 27 (Suppl 1): S106—S109.
- de Meijer PH, Lutterman JA, Van't Laar A. The absorption of subcutaneously injected insulin. Neth J Med 1989; 34: 210–227.
- Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990; 13: 473–477.
- Henriksen JE, Vaag A, Hansen IR, et aL. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Diab Med 1991; 8: 453–457.
- Vaag A, Handberg A, Lauritzen M, et aL. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990; 13:74–76.
- Thow JC, Home PD. Insulin injection technique BMJ 1990; 301: 3–4.
- Cryer PE. Hypoglycemia. Patho-physiology, Diagnosis and Treatment. New York: Oxford University Press, 1997; 96.
- Strauss K, Gols De H, et al. A pan-European epidemiological study of insulin injection technique in patients with diabetes. Pract Diabetes Int 2002; 19: 71–76.
- van Doom LG, Albeda A, Lytzen L. Insulin leakage and pain perception with NovoFine, 6 mm and NovoFine, 12 mm needle lengths in patients with type 1 and type 2 diabetes (Abstract). Diabetic Medicine 1998; 15: S50.
- Strauss K, Hannet I, McGonigle JM, et aL. Ultra-short (5 mm) insulin needles: trial results and clinical recommendations. Pract Diabetes Int 1999; 16: 218–222.
- Arendt-Nielsen L, Egekvist H. Bjerring P. Pain perception following controlled needle insertion: the impact of needle gauge. Diabetes 2005; 54 (Suppl): 420–P.
- Hanas R, Lytzen L, Ludvigsson J. Thinner needles do not influence injection pain, insulin leakage or bleeding in children and adolescents with type 1 diabetes. Pediatr Diabetes 2000; 1: 142–149.
- McGuire DB. Measuring Pain. In: Instruments for Clinical Health-Care Research. Frank-Stromborg M, Olsen SJ (eds). Sudbury, Massachusetts: Jones and Bartlett Publishers, 1997; 535.
- Soon DKW, de la Rena A, Teng CH, et al. More rapid pharmacokinetics and pharmacodynamics of insulin lispro delivered intradermally via a new microneedle system. (ADA meeting 2006, Abstract 426 P).
- Heinemann L, Pettis RJ, Hompesch M, et al. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection (ADA meeting 2006, Abstract 108-OR).